This Nuclear Tech Stock Grew Revenue 27%, But a Fund Still Slashed Its Stake

Nicholas Investment Partners sold 592,382 shares of Mirion Technologies in Q1 2026, an estimated $13.36 million transaction, leaving the position value down $14.11 million to $916,078. The filing is a modest negative signal for sentiment, but it appears more like portfolio rotation than a fundamental alarm, especially given Mirion’s 27.5% revenue growth in the latest quarter and reaffirmed 22% to 24% full-year revenue guidance. The stock was $18.92 as of May 14, up 6% over the past year.

Analysis

Nicholas’s sale looks more like portfolio de-risking than a fundamental indictment, but the signaling matters because MIR was a small enough position that trimming it likely reflects low marginal conviction rather than liquidity needs. That makes the next-order question less about this one holder and more about whether MIR can keep converting nuclear capex enthusiasm into durable free cash flow before the market tires of the story.

The key competitive dynamic is that MIR sits in the “picks-and-shovels” layer of the nuclear rebuild, but that layer is not equally elastic: BWXT and GEV have clearer direct exposure to plant upgrades, new build, and service monetization, while MIR still has to prove operating leverage. If utilities keep accelerating capex, MIR should benefit, but investors may prefer the names with more obvious near-term earnings translation, which can suppress MIR’s multiple even if revenue stays strong.

The contrarian setup is that the stock may be too cheap for the growth profile if nuclear spending turns into a multi-year cycle rather than a single-budget event. The near-term risk is not demand, but margin quality: if the company keeps growing 20%+ while staying near break-even on GAAP, the market may continue to treat it as a “good story, poor earnings” name. A sharper rerating likely requires either sustained EBITDA expansion over the next 2-3 quarters or another meaningful order beat that proves this is not just acquisition-assisted growth.

Key Decisions for Investors

• Long MIR vs short BWXT or GEV only as a tactical valuation-compression trade if you believe MIR is the cheapest way to own nuclear infrastructure beta; otherwise avoid outright long exposure until GAAP profitability trends improve over the next 2 quarters.
• If already long MIR, hedge with a short-dated covered call against the next earnings print to monetize elevated narrative premium while protecting against a sentiment-driven drawdown.
• Prefer long BWXT over MIR for the next 3-6 months if the goal is cleaner earnings translation from nuclear capex; BWXT appears better positioned for faster FCF conversion and less execution risk.
• Watch MIR only on pullbacks toward post-earnings support; initiate fresh longs only if the next update confirms margin expansion, not just revenue growth, because the rerating trigger is profitability, not top-line momentum.
• For event-driven accounts, consider a small long MIR / long-call structure into the next quarter if you expect another order acceleration beat; risk is limited premium, upside is a multiple expansion if the market starts pricing a multi-year nuclear cycle.